New drug duo takes on rare sarcomas
NCT ID NCT03282344
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether combining NKTR-214 and nivolumab can shrink or control advanced sarcoma that has spread. About 88 people aged 12 and older with certain sarcoma types will receive both drugs every three weeks. The main goal is to see how many patients have their tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NKTR-214 and nivolumab
What this could lead to
If it works, this combination could offer a new treatment option for advanced sarcoma, helping to shrink or control tumors.
What could go wrong
This is a small, early-phase pilot study. The drugs may not work for all sarcoma types, and side effects like immune reactions are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center (only recruiting to the Vascular/Angiosarcoma cohort)
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center (only recruiting to the Vascular/Angiosarcoma cohort)
New York, New York, 10065, United States